DoD Kidney Cancer, Idea Development Award | HT942524KCRPIDA

Opportunity Information: Apply for HT942524KCRPIDA

The FY24 DoD Kidney Cancer Research Program (KCRP) Idea Development Award (Funding Opportunity Number HT942524KCRPIDA) is a discretionary Department of the Army, USAMRAA grant opportunity designed to push kidney cancer research toward the program's long-term vision of eliminating kidney cancer. It is built for investigators proposing genuinely innovative, high-impact ideas that are still grounded in solid scientific evidence. Projects are expected to be hypothesis-driven, with a clearly testable central hypothesis supported by strong rationale and a well thought-out experimental plan. A major theme throughout the announcement is that creativity alone is not enough; applicants need to show that the idea is both novel and realistically executable, and that it could meaningfully change how kidney cancer is understood, detected, or managed rather than producing only incremental progress.

A strong application under this mechanism is expected to show deep, critical understanding of kidney cancer biology and/or clinical problems, and to translate that understanding into a research approach with clear feasibility. The proposal should lay out experimental strategies and methods in detail, specify needed resources, and document that those resources are available. The announcement also puts emphasis on anticipating real-world challenges: applicants should identify likely problems and pitfalls, and include alternate approaches if initial plans fail. Where relevant, a statistical analysis plan is required, and applications should include a power analysis to justify sample sizes and overall study design. This ties into a broader DoD emphasis on rigorous study design and reproducibility, including best practices like randomization, blinding, sample-size estimation, and transparent data handling.

Unlike some early-stage "idea" mechanisms, preliminary data are required for this award, but the preliminary data do not have to be in kidney cancer specifically. They can come from the PI's or collaborators' labs (published or unpublished) and may also draw on the published literature as long as they are relevant to kidney cancer or make a strong case for why the proposed approach is ready to be tested in the kidney cancer context. Innovation is a core review driver: the program is looking for research that introduces a new paradigm, challenges existing assumptions, or reframes persistent problems from a fresh angle. High-risk, high-reward concepts are welcome, but applicants must make a convincing case that success would have a major payoff for the field, patient care, and/or quality of life.

Impact is another key pillar. Competitive proposals should address a central and important question in kidney cancer research or clinical care and, if successful, should advance methods or concepts aligned with at least one of the FY24 KCRP Focus Areas. While the specific focus areas are referenced rather than listed in the text provided, the expectation is that the work will clearly map to KCRP priorities and move the field forward in a meaningful way. The program also highlights several broader, organizational-level emphasis areas that applicants may incorporate when relevant, including nuclear medicine approaches (such as precision imaging and targeted radiopharmaceutical strategies), women's health (including analysis of sex as a biological variable and relevance to outcomes for women), and metastatic cancer priorities aligned with the congressionally mandated Metastatic Cancer Task Force recommendations.

Personnel and team strength are treated as especially important for this award. Reviewers will look closely at whether the PI and team have demonstrated kidney cancer expertise or have built credible collaborations that bring that expertise to the project. Collaborations should be clearly documented, and multidisciplinary or multi-organizational teams are allowed and encouraged when they strengthen the science. The opportunity explicitly encourages applications from investigators in the military services as well as partnerships spanning academia, industry, the military, the Department of Veterans Affairs, and other federal agencies, particularly when those partnerships provide unique infrastructure, datasets, or access to distinctive clinical populations relevant to Service Members, Veterans, and the public. If the project depends on access to unique resources or databases, the application needs to explain what access already exists at submission and how access will be maintained throughout the work.

The announcement also includes a formal Partnering PI Option meant to support true co-led collaboration. Under this structure, two investigators are each designated as a PI and each receives a separate award, while working together on one integrated, synergistic project. One PI serves as the Initiating PI and handles most submission-related administrative responsibilities, while the other serves as the Partnering PI. Both are expected to contribute substantially and comparably to the intellectual development of the project and to major components like the Project Narrative and Statement of Work, and the application should make that equal intellectual ownership clear. Importantly, the program states that mentor-trainee pairings do not meet the intent of this partnering option; it is meant for peer-level collaboration that combines perspectives and capabilities.

On the human research side, the program allows studies involving human subjects and human anatomical substances, but it does not allow clinical trials. The opportunity uses the federal regulatory definition of a clinical trial (45 CFR 46.102): prospective assignment of human subjects to interventions to evaluate the effects on biomedical or behavioral health-related outcomes. The program draws a clear line between prohibited clinical trials and permitted clinical research that is observational or otherwise not designed to assess an intervention's safety, effectiveness, or efficacy. Examples of allowed clinical research include studies on disease mechanisms, diagnostics and detection (such as biomarkers or imaging), health disparities, technology development, epidemiology, behavioral studies, and outcomes or health services research, as long as they do not cross into interventional efficacy testing.

From a funding and logistics standpoint, awards are made as grants (31 USC 6304). The anticipated direct cost cap is up to $800,000 for a standard Idea Development Award, and up to $1.2 million in combined direct costs for the Partnering PI Option. The DoD planned to allocate about $18.56 million total to make roughly 13 awards, with final numbers depending on available federal funding and the results of peer and programmatic review. Awards supported with FY24 funds are expected to be made no later than September 30, 2025, and FY24 funds used for these awards are anticipated to expire for use on September 30, 2030. Eligibility is listed as unrestricted. The original application closing date shown is October 15, 2024, and the CFDA number associated with the opportunity is 12.420.

• The Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Kidney Cancer, Idea Development Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on 2024-07-11.
• Applicants must submit their applications by 2024-10-15. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 13 candidate(s).
• Eligible applicants include: Unrestricted.

Apply for HT942524KCRPIDA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: